Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04883827 · ClinicalTrials.gov registry record
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 180
- Enrollment target
NCT04883827 is a clinical trial that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 180 participants.
The verdict
NCT04883827 has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 180 participants
- Enrollment target
Study Summary
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
Interventions
- OTHER Blood collection
- OTHER Urine collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2021-01-06 |
| Est. Completion | 2023-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04883827
The ClinicalTrials.gov registry entry for NCT04883827 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood collection is the first listed.
NCT04883827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04883827 about?
NCT04883827 is a clinical study titled "Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer". This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
What is the current status of trial NCT04883827?
This trial is currently completed. The enrollment target is 180 participants. The study started on 2021-01-06. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT04883827?
The interventions under investigation include: Blood collection (OTHER), Urine collection (OTHER).
Who is sponsoring clinical trial NCT04883827?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.